Skip to main content
OpenTrials

Clinical trial condition

Metastatic Hormone-sensitive Prostate Cancer

Explore clinical trials studying Metastatic Hormone-sensitive Prostate Cancer. Study availability and eligibility vary by location and protocol.

21 public trials 5 recruiting studies
Refine in advanced search Browse all conditions

Metastatic Hormone-sensitive Prostate Cancer trial results

Completed

A Study to Learn How Well Darolutamide Administered Together With Androgen Deprivation Therapy (ADT) Works in Men With Metastatic Hormone-sensitive Prostate Cancer. Results Will be Compared With ADT Alone From a Previously Conducted Study.

NCT05059236

Conditions
Genital Diseases, Genital Diseases, Male, Genital Neoplasms, Male, +8 more
Locations
  • Urology Centers of Alabama, PC - Homewood Homewood, Alabama, United States
  • Arizona Urology Specialists - Tucson - W Orange Grove Tucson, Arizona, United States
  • Tower Urology Los Angeles, California, United States
  • UCI Health Center for Urological Care Orange, California, United States
View all 31 locations
View Trial Details
Completed

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)-China Extension

NCT04934722

Conditions
Metastatic Hormone-sensitive Prostate Cancer, Parkinson Disease 4, Autosomal Dominant Lewy Body
Locations
  • Peking University First Hospital ( Site 0800) Beijing, Beijing Municipality, China
  • Beijing Cancer Hospital ( Site 0802) Beijing, Beijing Municipality, China
  • Chongqing Cancer Hospital ( Site 0815) Chongqing, Chongqing Municipality, China
  • The First Affiliated Hospital of Xiamen University (Site 0816) Xiamen, Fujian, China
View all 24 locations
View Trial Details
Completed

A Study for the Participants With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Treated With Androgen Deprivation Therapy (ADT) Plus Apalutamide or Enzalutamide

NCT05901649

Conditions
Metastatic Hormone-sensitive Prostate Cancer
Locations
  • Akh Wien Vienna, Austria
  • Klinikum Wels Grieskirchen Wels, Austria
  • Institut Sainte Catherine Avignon, France
  • Institut Bergonie Bordeaux, France
View all 53 locations
View Trial Details
Completed

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)

NCT04191096

Conditions
Metastatic Hormone-sensitive Prostate Cancer, Parkinson Disease 4, Autosomal Dominant Lewy Body
Locations
  • Alaska Clinical Research Center ( Site 0274) Anchorage, Alaska, United States
  • Providence Alaska Medical Center ( Site 0276) Anchorage, Alaska, United States
  • City of Hope Medical Center ( Site 0217) Duarte, California, United States
  • UCLA Hematology/Oncology - Santa Monica ( Site 0241) Los Angeles, California, United States
View all 234 locations
View Trial Details
Completed

Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer

NCT00309985

Conditions
Metastatic Hormone-sensitive Prostate Cancer
Locations
  • Providence Cancer Center Anchorage, Alaska, United States
  • Fairbanks Cancer Treatment Center at Fairbanks Memorial Hospital Fairbanks, Alaska, United States
  • Mayo Clinic Hospital Phoenix, Arizona, United States
  • Mayo Clinic Scottsdale Scottsdale, Arizona, United States
View all 343 locations
View Trial Details

Related conditions